HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

A Luminacin D Analog HL142 Inhibits Ovarian Tumor Growth and Metastasis by Reversing EMT and Attenuating the TGFβ and FAK Pathways

This item is licensed under:Creative Commons Attribution 4.0 International

Files in This Item:
Yue 2021 Luminacin D Analog HL142 Inhibits Ovarian.pdf2.62 MBPDFView/Open
Please use this identifier to cite or link to this item:

Title: A Luminacin D Analog HL142 Inhibits Ovarian Tumor Growth and Metastasis by Reversing EMT and Attenuating the TGFβ and FAK Pathways
Authors: Wang, Baojin Browse this author
Li, Hanxuan Browse this author
Zhao, Xinxin Browse this author
Zhang, Wenjing Browse this author
Zhao, Guannan Browse this author
Wu, Zhongzhi Browse this author
Zhang, Ruitao Browse this author
Dong, Peixin Browse this author →KAKEN DB
Watari, Hidemichi Browse this author
Tigyi, Gabor Browse this author
Li, Wei Browse this author
Yue, Junming Browse this author
Keywords: Luminacin D analog
ovarian tumor
Issue Date: 25-Jul-2021
Journal Title: Journal of Cancer
Volume: 12
Issue: 18
Start Page: 5654
End Page: 5663
Publisher DOI: 10.7150/jca.61066
Abstract: Epithelial to mesenchymal transition (EMT) is known to contribute to tumor metastasis and chemoresistance. Reversing EMT using small molecule inhibitors to target EMT associated gene expression represents an effective strategy for cancer treatment. The purpose of this study is to test whether a new luminacin D analog HL142 reverses EMT in ovarian cancer (OC) and has the therapeutic potential for OC. We chemically synthesized HL142 and tested its functions in OC cells in vitro and its efficacy in inhibiting ovarian tumor growth and metastasis in vivo using orthotopic OC mouse models.We first demonstrate that ASAP1 is co-amplified and interacts with the focal adhesion kinase (FAK) protein in serous ovarian carcinoma. HL142 inhibits ASAP1 and its interaction protein FAK in highly invasive OVCAR8 and moderately invasive OVCAR3 cells. HL142 inhibits EMT phenotypic switch, accompanied by upregulating epithelial marker E-cadherin and cytokeratin-7 and downregulating mesenchymal markers vimentin, β-catenin, and snail2 in both cell lines. Functionally, HL142 inhibits proliferation, colony formation, migration, and invasion. HL142 also sensitizes cell responses to chemotherapy drug paclitaxel treatment and inhibits ovarian tumor growth and metastasis in orthotopic OC mouse models. We further show that HL142 attenuates the TGFβ and FAK pathways in vitro using OC cells and in vivousing orthotopic mouse models.
Type: article
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 董 培新

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 - Hokkaido University